Scarica l'app Stockscreener
2.25
0.88%
-0.02
Dopo l'orario di chiusura:
2.21
-0.04
-1.78%
Precedente Chiudi:
$2.27
Aprire:
$2.32
Volume 24 ore:
2.57M
Relative Volume:
0.78
Capitalizzazione di mercato:
$419.94M
Reddito:
$7.12M
Utile/perdita netta:
$-24.17M
Rapporto P/E:
-9.244
EPS:
-0.2434
Flusso di cassa netto:
$-41.95M
1 W Prestazione:
-0.44%
1M Prestazione:
-8.91%
6M Prestazione:
+25.70%
1 anno Prestazione:
+624.87%
Intervallo 1D:
$2.215
$2.3667
Intervallo di 1 settimana:
$2.215
$2.49
Portata 52W:
$0.2851
$3.105
Ovid Therapeutics Inc Stock (OVID) Company Profile
Nome
Ovid Therapeutics Inc
Settore
Industria
Telefono
212-776-4381
Indirizzo
441 NINTH AVENUE, 14TH FLOOR, NEW YORK, NY
Compare OVID vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
OVID
Ovid Therapeutics Inc
|
2.25 | 423.67M | 7.12M | -24.17M | -41.95M | -0.2434 |
VRTX
Vertex Pharmaceuticals Inc
|
466.79 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
612.50 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
903.75 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
286.41 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
165.81 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ovid Therapeutics Inc Stock (OVID) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-11 | Iniziato | Roth Capital | Buy |
| 2025-11-17 | Iniziato | Leerink Partners | Outperform |
| 2025-10-09 | Iniziato | Oppenheimer | Outperform |
| 2025-08-08 | Ripresa | B. Riley Securities | Buy |
| 2024-06-18 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-04-30 | Iniziato | B. Riley Securities | Buy |
| 2024-04-29 | Iniziato | H.C. Wainwright | Buy |
| 2024-04-05 | Iniziato | Wedbush | Outperform |
| 2023-12-21 | Iniziato | BTIG Research | Buy |
| 2023-10-13 | Iniziato | Oppenheimer | Outperform |
| 2021-04-20 | Downgrade | Cantor Fitzgerald | Buy → Neutral |
| 2021-03-03 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-12-02 | Downgrade | Citigroup | Buy → Neutral |
| 2020-12-02 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-09-04 | Iniziato | RBC Capital Mkts | Outperform |
| 2018-04-20 | Iniziato | Ladenburg Thalmann | Buy |
Mostra tutto
Ovid Therapeutics Inc Borsa (OVID) Ultime notizie
Ovid Therapeutics Inc.(NasdaqCM: OVID) added to S&P Biotechnology Select Industry Index - marketscreener.com
Ovid Therapeutics Inc (OVID) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Ovid Therapeutics (NASDAQ: OVID) grants director Anna Greka 130,000 stock options - Stock Titan
Ovid Therapeutics (OVID) director files initial Form 3 - Stock Titan
Ovid Therapeutics Inc (OVID) Valuation: PE, PB & Fair Value Analysis - TradingKey
Ovid Therapeutics Inc (OVID) Institutional Confidence - TradingKey
Ovid Therapeutics Inc (OVID) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Ovid Therapeutics Inc (OVID) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Ovid Therapeutics Inc (OVID) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Ovid Therapeutics Inc (OVID) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Ovid Therapeutics Inc (OVID) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Ovid Therapeutics Inc (OVID) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
OVID: Multiple clinical milestones and strong financial runway position the pipeline for significant value creation - TradingView
Ovid Therapeutics Shareholders Back Board and Governance Proposals - The Globe and Mail
Ovid Therapeutics (OVID) Slips 1.97% as Shares Test Key Support LevelsStrong Buy Stocks - newsline.com
Ovid Therapeutics (NASDAQ: OVID) shareholders approve director, pay and auditor - Stock Titan
Ovid Therapeutics Inc Annual Shareholders Meeting Transcript - GuruFocus
Ovid Board Move Puts Scientific Strategy Back In Focus - Kalkine Media
Ovid Therapeutics Expands Board, Appoints New Scientific Director - The Globe and Mail
Ovid Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
Ovid Therapeutics appoints Anna Greka to board of directors - Investing.com UK
Ovid Therapeutics appoints Anna Greka to board of directors By Investing.com - Investing.com Canada
Anna Greka joins Ovid Therapeutics (NASDAQ: OVID) board, expanding it to seven - Stock Titan
Ovid Therapeutics Appoints Leading Physician-Scientist and - GlobeNewswire
OVIDOvid Therapeutics Inc Stock Price and Quote - Finviz
Ovid Therapeutics (OVID) Gains Nearly 4% as Shares Test Key ResistanceUnusual Put Volume - newsline.com
Will Ovid’s golden age of KCC2 metamorph CNS? - BioWorld News
H.C. Wainwright Maintains Ovid Therapeutics(OVID.US) With Buy Rating, Maintains Target Price $4 - Moomoo
OVID SEC FilingsOvid Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Point72 (OVID) discloses shared 1.3% position, including warrants - Stock Titan
Eventide (OVID) discloses 12.8M-share, 7.3% position in Ovid Therapeutics - Stock Titan
Ovid Therapeutics (OVID) Schedule 13G: Sirenia/manager report 9.9% stake - Stock Titan
Balyasny group holds 5.33% of Ovid (NASDAQ: OVID) across funds - Stock Titan
[SCHEDULE 13G/A] Ovid Therapeutics Inc. Amended Passive Investment Disclosure - Stock Titan
Jeremy Levin reports 4.5% stake in Ovid Therapeutics (NASDAQ: OVID) - Stock Titan
We're Hopeful That Ovid Therapeutics (NASDAQ:OVID) Will Use Its Cash Wisely - Yahoo Finance
Wedbush Maintains Ovid Therapeutics(OVID.US) With Buy Rating, Maintains Target Price $7 - Moomoo
LifeSci Capital Maintains Ovid Therapeutics(OVID.US) With Buy Rating, Maintains Target Price $5 - Moomoo
B.Riley reiterates Buy on Ovid Therapeutics stock, $5 target By Investing.com - Investing.com Australia
B.Riley reiterates Buy on Ovid Therapeutics stock, $5 target - Investing.com India
TD Cowen Maintains Ovid Therapeutics(OVID.US) With Buy Rating - Moomoo
Ovid Therapeutics 1Q Research and Development Expenses $11.2M >OVID - Moomoo
William Blair Maintains Ovid Therapeutics(OVID.US) With Buy Rating - Moomoo
Ovid Therapeutics earnings matched, revenue fell short of estimates By Investing.com - Investing.com Canada
OVID Sets Stage for Future Growth with Promising Pipeline Develo - GuruFocus
Ovid Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
Ovid Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Ovid Therapeutics Reports Q1 2026 Results, Advances OV329 and OV4071 Clinical Programs, and Expands Pipeline for Pediatric Epilepsy and Psychosis 123 - Minichart
Ovid Therapeutics stock rises 4% on in-line results, pipeline progress By Investing.com - Investing.com South Africa
Ovid Therapeutics stock rises 4% on in-line results, pipeline progress - Investing.com UK
Ovid Therapeutics Inc Azioni (OVID) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Ovid Therapeutics Inc Azioni (OVID) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| ALEXANDER MARGARET A. | President and CEO |
Feb 23 '26 |
Sale |
1.45 |
11,656 |
16,901 |
61,750 |
| Rona Jeffrey A | CBFO |
Feb 23 '26 |
Sale |
1.45 |
8,541 |
12,384 |
88,188 |
0.57%
1.15%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):